✦ LIBER ✦

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer

✍ Scribed by Shanu Modi; Andrew D. Seidman; Maura Dickler; Mark Moasser; Gabriella D’Andrea; Mary Ellen Moynahan; Jennifer Menell; Katherine S. Panageas; Lee K. Tan; Larry Norton; Clifford A. Hudis

Publisher: Springer US
Year: 2005
Tongue: English
Weight: 255 KB
Volume: 90
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-004-3974-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of piroxantrone in metast

Phase II trial of piroxantrone in metastatic breast cancer

✍ Peter M. Ravdin; Stephanie Green; James H. Doroshow; Silvana Martino 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 274 KB

Imatinib mesylate in the treatment of sy

Imatinib mesylate in the treatment of systemic mastocytosis : A phase II trial

✍ Helga J. Droogendijk; Hanneke J. C. Kluin-Nelemans; Jaap J. van Doormaal; Arnold 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB

Phase II trial of edatrexate in patients

Phase II trial of edatrexate in patients with metastatic colorectal cancer

✍ Gerald H. Clamon; Charles E. Riggs; Robert Dreicer; Raymond J. Hohl 📂 Article 📅 1995 🏛 Springer US 🌐 English ⚖ 242 KB

Multicenter Phase II trial of high-dose

Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma : Significant toxicity with no clinical efficacy

✍ Ken Wyman; Michael B. Atkins; Victor Prieto; Omar Eton; David F. McDermott; Fran 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

Phase II study of ionidamine in patients

Phase II study of ionidamine in patients with metastatic breast cancer

✍ H. Ian Robins; Donna S. Neuberg; Al B. Benson; Kishan J. Pandya; Douglass C. Tor 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 193 KB

The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m 2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxi

A phase II trial of docetaxel (Taxotere®

A phase II trial of docetaxel (Taxotere®) as second-line chemotherapy in patients with metastatic breast cancer

✍ Martina Baur; Allan T. van Oosterom; Véronique Diéras; Michele Tubiana-Hulin; R. 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 385 KB